GSA Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $623K | Buy |
70,408
+55,804
| +382% | +$494K | 0.04% | 763 |
|
|
2025
Q1 | $114K | Buy |
+14,604
| New | +$114K | 0.01% | 1482 |
|
|
2024
Q3 | – | Sell |
-10,385
| Closed | -$146K | – | 1588 |
|
|
2024
Q2 | $146K | Sell |
10,385
-37,211
| -78% | -$523K | 0.01% | 1496 |
|
|
2024
Q1 | $804K | Buy |
+47,596
| New | +$804K | 0.06% | 589 |
|
|
2022
Q1 | – | Sell |
-39,273
| Closed | -$317K | – | 1403 |
|
|
2021
Q4 | $317K | Sell |
39,273
-17,875
| -31% | -$144K | 0.04% | 889 |
|
|
2021
Q3 | $560K | Buy |
57,148
+4,215
| +8% | +$41.3K | 0.06% | 635 |
|
|
2021
Q2 | $356K | Buy |
+52,933
| New | +$356K | 0.04% | 832 |
|
|
2020
Q4 | – | Sell |
-22,390
| Closed | -$113K | – | 1203 |
|
|
2020
Q3 | $113K | Buy |
22,390
+7,780
| +53% | +$39.3K | 0.02% | 1113 |
|
|
2020
Q2 | $118K | Buy |
+14,610
| New | +$118K | 0.07% | 454 |
|
|
2018
Q4 | – | Sell |
-46,597
| Closed | -$205K | – | 1342 |
|
|
2018
Q3 | $205K | Sell |
46,597
-188,620
| -80% | -$830K | 0.01% | 1481 |
|
|
2018
Q2 | $1.44M | Sell |
235,217
-80,743
| -26% | -$495K | 0.07% | 476 |
|
|
2018
Q1 | $2.3M | Buy |
315,960
+64,927
| +26% | +$473K | 0.12% | 214 |
|
|
2017
Q4 | $2.06M | Buy |
251,033
+105,610
| +73% | +$866K | 0.13% | 226 |
|
|
2017
Q3 | $1.53M | Sell |
145,423
-54,790
| -27% | -$575K | 0.1% | 275 |
|
|
2017
Q2 | $2.21M | Buy |
200,213
+18,056
| +10% | +$199K | 0.14% | 131 |
|
|
2017
Q1 | $1.76M | Buy |
+182,157
| New | +$1.76M | 0.09% | 317 |
|